An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
PhaseBio Pharmaceuticals to Present at 23rd Annual H.C. Wainwright Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced that CFO John Sharp will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be accessible on demand starting at 7:00am ET on September 13, 2021. Interested viewers can find the live and archived webcast on the company’s website for 90 days post-event. PhaseBio focuses on novel therapies for cardiopulmonary diseases, including bentracimab, pemziviptadil, and PB6440, utilizing a proprietary elastin-like polypeptide technology platform.
Positive
None.
Negative
None.
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Financial Officer John Sharp will provide a company overview at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be available on demand beginning at 7:00am ET on Monday, September 13, 2021.
Interested parties can access the live and archived webcast of the event on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.
